Abraham R.
- Country
- The Netherlands
- Department
- Reumatologie & Klinische Immunologie
Research Overview
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)
- A Phase 3 Randomized Controlled Trial to Evaluate the Efficacy and Safety of Rilzabrutinib in Adults with Active IgG4-Related Disease
- Efficacy and Safety of Depemokimab vs. Mepolizumab in Adults with Relapsing/Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Data & Insights
Has run more than one trial at 24 of 83 partner sites.
Specializations
Autoimmune Disorders
This investigator specializes in treating Eosinophilic Granulomatosis with Polyangiitis (EGPA), with particular focus on managing relapsing and refractory cases of this rare autoimmune condition.
- Vasculitis Management
- Eosinophilic Disorders
- Autoimmune Disease Treatment
The therapeutic approach involves exploring innovative treatment options for patients whose condition persists despite standard interventions.
Immunology
The investigator focuses on advancing the understanding of immunological interventions in systemic vasculitis, particularly examining novel biological therapies for autoimmune conditions.
- Biological Therapy Development
- Immunological Response
- Treatment Resistance
Their work encompasses the evaluation of long-acting therapeutic agents in the management of chronic autoimmune disorders.
Therapeutic Innovation
The investigator specializes in comparing the effectiveness of different targeted biological treatments for patients with resistant autoimmune conditions.
- Comparative Treatment Studies
- Long-term Disease Management
- Standard of Care Enhancement
A key focus is on developing treatment strategies that improve long-term outcomes for patients with challenging autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.